Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 May;39(5):1162–1165. doi: 10.1128/aac.39.5.1162

In vitro activity of roxithromycin against the Mycobacterium tuberculosis complex.

N Rastogi 1, K S Goh 1, P Ruiz 1, M Casal 1
PMCID: PMC162701  PMID: 7625806

Abstract

Roxithromycin has recently been shown to possess significant in vitro activity against a variety of atypical mycobacteria such as the M. avium complex, M. scrofulaceum, M. szulgai, M. malmoense, M. xenopi, M. marinum, and M. kansasii and rare pathogens like M. chelonei and M. fortuitum. In the present investigation, screening of its in vitro activity was further extended by testing it against 34 strains belonging to the M. tuberculosis complex (including M. tuberculosis, M. africanum, M. bovis, and M. bovis BCG). The MICs were determined by the radiometric BACTEC 460-TB methodology at pHs of both 6.8 and 7.4, as well as with 7H10 agar medium by the 1% proportion method. With the exception of M. bovis BCG (MIC ranges, 0.5 to 4 micrograms/ml at pH 6.8 and 0.25 to 2 micrograms/ml at pH 7.4), MICs for all of the isolates were significantly greater (MIC ranges, 32 to > 64 micrograms/ml at pH 6.8 and 16 to > 32 micrograms/ml at pH 7.4) than those reported previously for atypical mycobacteria. Roxithromycin MICs of 64 or > 64 micrograms/ml for all of the M. tuberculosis isolates screened were found by the 7H10 agar medium method. Roxithromycin, however, showed a pH-dependent bactericidal effect against M. tuberculosis because the drug was relatively more active when it was used at pH 7.4 than when it was used at pH 6.8. We conclude that roxithromycin per se is not a drug of choice for the treatment of M. tuberculosis infection or disease; however, considering its pharmacokinetics, eventual anti-tubercle bacillus activity in an in vivo system cannot yet be excluded. We suggest that the use of roxithromycin in chemoprophylactic regimens for the prevention of opportunistic infections (including M. avium complex infections) in patients with AIDS should be carefully monitored, and patients should be enrolled in such a regimen only after it has been excluded that the patient das an underlying infection of disease caused by M. tuberculosis.

Full Text

The Full Text of this article is available as a PDF (236.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bermudez L. E., Young L. S. Activities of amikacin, roxithromycin, and azithromycin alone or in combination with tumor necrosis factor against Mycobacterium avium complex. Antimicrob Agents Chemother. 1988 Aug;32(8):1149–1153. doi: 10.1128/aac.32.8.1149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Casal M., Rodriguez F., Villalba R. In vitro susceptibility of Mycobacterium avium to a new macrolide (RU-28965). Chemotherapy. 1987;33(4):255–258. doi: 10.1159/000238504. [DOI] [PubMed] [Google Scholar]
  3. Casal M., Rodríguez F., Gutierrez J., Ruiz P., Benavente M. C., Villalba R., Moreno G. Promising new drugs in the treatment of tuberculosis and mycobacteriosis. J Chemother. 1989 Feb;1(1):39–45. doi: 10.1080/1120009x.1989.11738862. [DOI] [PubMed] [Google Scholar]
  4. Crowle A. J., Dahl R., Ross E., May M. H. Evidence that vesicles containing living, virulent Mycobacterium tuberculosis or Mycobacterium avium in cultured human macrophages are not acidic. Infect Immun. 1991 May;59(5):1823–1831. doi: 10.1128/iai.59.5.1823-1831.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Gemmell C. G. Macrolides and host defences to respiratory tract pathogens. J Hosp Infect. 1991 Sep;19 (Suppl A):11–19. doi: 10.1016/0195-6701(91)90213-r. [DOI] [PubMed] [Google Scholar]
  6. Heifets L. B., Lindholm-Levy P. J., Comstock R. D. Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. Am Rev Respir Dis. 1992 Apr;145(4 Pt 1):856–858. doi: 10.1164/ajrccm/145.4_Pt_1.856. [DOI] [PubMed] [Google Scholar]
  7. Kirst H. A., Sides G. D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother. 1989 Sep;33(9):1419–1422. doi: 10.1128/aac.33.9.1419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Maugein J., Fourche J., Mormede M., Pellegrin J. L. Sensibilité in vitro de Mycobacterium avium et Mycobacterium xenopi a l'érythromycine, roxithromycine et doxycycline. Pathol Biol (Paris) 1989 Jun;37(5 Pt 2):565–567. [PubMed] [Google Scholar]
  9. Rastogi N., Goh K. S., Bryskier A. Activities of roxithromycin used alone and in combination with ethambutol, rifampin, amikacin, ofloxacin, and clofazimine against Mycobacterium avium complex. Antimicrob Agents Chemother. 1994 Jun;38(6):1433–1438. doi: 10.1128/aac.38.6.1433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Rastogi N., Goh K. S., Bryskier A. In vitro activity of roxithromycin against 16 species of atypical mycobacteria and effect of pH on its radiometric MICs. Antimicrob Agents Chemother. 1993 Jul;37(7):1560–1562. doi: 10.1128/aac.37.7.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Rastogi N., Goh K. S., David H. L. Drug susceptibility testing in tuberculosis: a comparison of the proportion methods using Lowenstein-Jensen, Middlebrook 7H10 and 7H11 agar media and a radiometric method. Res Microbiol. 1989 Jul-Aug;140(6):405–417. doi: 10.1016/0923-2508(89)90016-8. [DOI] [PubMed] [Google Scholar]
  12. Rastogi N., Goh K. S. Effect of pH on radiometric MICs of clarithromycin against 18 species of mycobacteria. Antimicrob Agents Chemother. 1992 Dec;36(12):2841–2842. doi: 10.1128/aac.36.12.2841. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Rastogi N., McFadden J. J. Mycobacteria and AIDS: epidemiological and genetic markers, virulence factors and interactions with the immune system. Res Microbiol. 1992 May;143(4):361–362. doi: 10.1016/0923-2508(92)90046-q. [DOI] [PubMed] [Google Scholar]
  14. Siddiqi S. H., Hawkins J. E., Laszlo A. Interlaboratory drug susceptibility testing of Mycobacterium tuberculosis by a radiometric procedure and two conventional methods. J Clin Microbiol. 1985 Dec;22(6):919–923. doi: 10.1128/jcm.22.6.919-923.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Small P. L., Ramakrishnan L., Falkow S. Remodeling schemes of intracellular pathogens. Science. 1994 Feb 4;263(5147):637–639. doi: 10.1126/science.8303269. [DOI] [PubMed] [Google Scholar]
  16. Sturgill-Koszycki S., Schlesinger P. H., Chakraborty P., Haddix P. L., Collins H. L., Fok A. K., Allen R. D., Gluck S. L., Heuser J., Russell D. G. Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase. Science. 1994 Feb 4;263(5147):678–681. doi: 10.1126/science.8303277. [DOI] [PubMed] [Google Scholar]
  17. Williams J. D., Sefton A. M. Comparison of macrolide antibiotics. J Antimicrob Chemother. 1993 Mar;31 (Suppl 100):11–26. doi: 10.1093/jac/31.suppl_c.11. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES